香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 Cryofocus Medtech (Shanghai) Co., Ltd. 康灃生物科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6922） 根據一般授權認購新H股 根據一般授權認購新H股 於2026年1月12日（交易時段後），本公司與認購人訂立認購協議，據此，本公 司已有條件同意配發及發行，而認購人已有條件同意認購合計7,460,000股H股 （認購價為每股認購股份5.36港元），相當於(i)於本公告日期現有已發行H股數目 約5.20%及現有已發行股份數目約3.12%；及(ii)經配發及發行認購股份擴大後已 發行H股數目約4.94%及現有已發行股份數目約3.03%。 認購價每股認購股份5.36港元較(i)於認購協議日期在聯交所所報收市價每股H股 6.52港元折讓約17.79%；及(ii)於緊接認購 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06922 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 143,438,579 | RMB | | 1 RMB | | 143,438,579 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 143,438,579 | RMB | | 1 RMB | | 143,438,579 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | ...

Group 1 - China Petroleum & Chemical Corporation (Sinopec) launched a special action to enhance the market value of its listed companies during an investor communication event held on December 16 [1] - The action aims to improve investment value and increase shareholder returns through three main aspects: enhancing governance efficiency, improving the return system, and optimizing capital layout [1][2] - The governance efficiency will focus on management enhancement, strategic development planning, capital operation, and talent development in the capital market [1] - The return system will emphasize quality information disclosure, investor relations management, and a stable cash dividend policy, along with share buybacks to enhance shareholder returns [1] - The capital layout optimization will involve mergers and acquisitions, equity financing, and adjustments to the industrial layout to enhance the overall market value of listed companies during the 14th Five-Year Plan period [1] Group 2 - The event included executives from nine listed companies under Sinopec, as well as representatives from state-owned securities regulatory agencies, central enterprises, and financial institutions [2] Group 3 - The U.S. stock market saw the Dow Jones Industrial Average and S&P 500 decline for three consecutive days, while large tech stocks mostly rose [3] - The Dow Jones fell by 302.3 points to close at 48,114.26, a decrease of 0.62%, and the S&P 500 dropped by 16.25 points to 6,800.26, a decline of 0.24% [3] - The Nasdaq Composite Index increased by 54.05 points to 23,111.46, a rise of 0.23%, with Tesla reaching a historic high [3] Group 4 - The European Union is preparing to propose easing emissions regulations for new cars, effectively abolishing the ban on internal combustion engines, allowing manufacturers to slow down the rollout of electric vehicles [4] - This move aligns the EU's policies more closely with the U.S., where former President Trump is rolling back automotive efficiency standards [4] - Ford has announced a $19.5 billion charge related to its electric vehicle business overhaul due to the profitability challenges faced by global automakers [4] Group 5 - The Ministry of Commerce of China announced that starting December 17, 2025, anti-dumping duties will be imposed on imported pork and pork products from the EU for a period of five years [5] - The anti-dumping duties will be calculated based on the customs-determined taxable price of the imported goods [5] Group 6 - China Energy Engineering Corporation announced that the first phase of the world's largest green hydrogen and ammonia integrated project, the Zhongnengjian Songyuan Hydrogen Energy Industrial Park, has officially commenced operations [6][7] Group 7 - Kangfeng Biotechnology received approval from the National Medical Products Administration for its anti-reflux system, enhancing the diversity of its product portfolio [8] Group 8 - Hansoh Pharmaceutical entered into a licensing agreement with Glenmark for the commercialization of Amivantamab, a treatment for non-small cell lung cancer [9] - The agreement includes upfront payments and potential milestone payments exceeding $1 billion, along with tiered royalties on net sales in the licensed regions [9] Group 9 - Shandong High Holding signed an EPC contract for a wind farm project in Guangxi, marking its active integration into the clean energy sector [10] Group 10 - MMG Australia Limited and Minmetals North-Europe signed a sales agreement for Rosebery concentrate, covering 100% of production for 2026 and 2027, with an expected annual output of approximately 6,000 dry metric tons [11] Group 11 - China General Nuclear Power Corporation announced the commencement of full construction for the Ningde Unit 6 nuclear reactor, marking a significant milestone in its development [12] Group 12 - Daqi Pharmaceutical received approval in Malaysia for its drug Selinexor to treat relapsed or refractory diffuse large B-cell lymphoma in adult patients [13] Group 13 - CIMC Enric's first large-scale biomass methanol project in Guangdong officially commenced production, with an expected annual capacity of 50,000 tons [14] - The project aims to achieve full operational capacity before the 2026 Spring Festival, contributing significantly to revenue [14][15] - The company is also exploring a second phase of the project, with plans for an annual output of 200,000 tons by 2027 [15]

Core Viewpoint - The approval of the anti-reflux system by the National Medical Products Administration enhances the product portfolio of the company, making it more diverse and comprehensive [1] Group 1: Product Details - The anti-reflux system consists of an implanted anti-reflux device and esophageal measurement tools [1] - It is designed for use in magnetic enhancement surgery of the lower esophageal sphincter to treat gastroesophageal reflux disease [1] - The system works by implanting a device with magnetic beads in the functional area of the lower esophageal sphincter, which increases the tension of the sphincter to restore its anti-reflux function [1]

Core Viewpoint - Kangfeng Biotech-B (06922) has received approval from the National Medical Products Administration for its anti-reflux system, enhancing the diversity of its product portfolio [1] Group 1: Product Approval - The anti-reflux system consists of an implanted anti-reflux device and esophageal measurement tools, which are set to be available by December 15, 2025 [1] - The approval signifies a significant milestone for the company, indicating progress in its product development and regulatory compliance [1] Group 2: Product Functionality - The anti-reflux system is a self-developed surgical instrument designed for use in magnetic enhancement surgery of the lower esophageal sphincter to treat gastroesophageal reflux disease [1] - The system works by implanting a device in the functional area of the lower esophageal sphincter, where magnetic beads create an attractive force to enhance the tension of the sphincter, thereby restoring its anti-reflux function [1]

Core Viewpoint - Kangfeng Biotech-B (06922.HK) announced that its anti-reflux system has received approval from the National Medical Products Administration, enhancing the diversity of its product offerings [1] Group 1: Product Approval - The anti-reflux system consists of an implanted anti-reflux device and esophageal measurement tools, which received approval on December 15, 2025 [1] - The approval signifies a significant milestone for the company, allowing it to expand its product structure [1] Group 2: Product Functionality - The anti-reflux system is a self-developed surgical instrument designed for the treatment of gastroesophageal reflux disease (GERD) during magnetic enhancement surgery of the lower esophageal sphincter [1] - The system works by implanting a device in the functional area of the lower esophageal sphincter, where magnetic beads create an attractive force to enhance the tension of the sphincter, thereby restoring its anti-reflux function [1]

康灃生物科技（上海）股份有限公司 Cryofocus Medtech (Shanghai) Co., Ltd. （於中華人民共和國註冊成立的股份有限公司） （股份代號：6922） 自願公告 抗胃食管反流系統獲得國家藥監局批文 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 1 本公司無法保證抗胃食管反流系統的未來前景。本公司股東及潛在投資者於買賣 本公司證券時務請審慎行事。 承董事會命 康灃生物科技（上海）股份有限公司 董事會主席 李克儉先生 本公告乃由康灃生物科技（上海）股份有限公司（「本公司」，連同其附屬公司統稱 為「本集團」）自願作出，以告知本公司股東及潛在投資者有關本集團業務的最新 進展。 本公司欣然宣布，於2025年12月15日，本集團的抗胃食管反流系統（「抗胃食管反 流系統」），由植入式抗胃食管反流器及食管測量工具組成，已獲得國家藥品監督 管理局（「國家藥監局」）授出的批文。隨著抗胃食管反流系統的獲批，本集團的產 品結構變得更加豐富且多樣化 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06922 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 143,438,579 | RMB | | 1 RMB | | 143,438,579 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 143,438,579 | RMB | | 1 RMB | | 143,438,579 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康灃生物科技（上海）股份有限公司 (「本公司」) (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06922 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 143,438,579 | RMB | | 1 RMB | | 143,438,579 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 143,438,579 | RMB | | 1 RMB | | 143,438,5 ...

康灃生物科技（上海）股份有限公司 章程 | | | | 章程 | | | | | --- | --- | --- | --- | | 目 | 錄 | | 1 | | 第一章 | | 總則 | 2 | | 第二章 | | 經營宗旨及範圍 | 4 | | 第三章 | | 股份和註冊資本 | 5 | | 第四章 | | 減資和購回股份 | 10 | | 第五章 | | 購買公司股份的財務資助 | 13 | | 第六章 | | 股票和股東名冊 | 15 | | 第七章 | | 股東的權利和義務 | 20 | | 第八章 | | 股東大會 | 23 | | 第九章 | | 董事會 | 34 | | 第十章 | | 董事會秘書 | 41 | | 第十一章 | | 公司秘書 | 42 | | 第十二章 | | 總經理 | 43 | | 第十三章 | | 公司董事、高級管理人員的資格和義務 | 44 | | 第十四章 | | 財務會計制度與利潤分配 | 50 | | 第十五章 | | 會計師事務所的聘任 | 53 | | 第十六章 | | 合併、分立、解散和清算 | 55 | | 第十七章 | | 公司解散和清算 | 56 ...